pentobarbital will reduce the level or influence of lumefantrine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration with powerful CYP3A4 inducers may result in decreased serum concentrations and loss of antimalarial efficacypentobarbital will minimize the extent or influence of budesonide by affecting hepa